|Bid||3.0400 x 3200|
|Ask||3.0500 x 21500|
|Day's Range||2.9900 - 3.2000|
|52 Week Range||2.0900 - 15.8640|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.41|
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2022, on Monday, August 15, 2022, beginning at 4:30 p.m. ET.
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Directors, effective August 2, 2022. Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives.
We analyzed the 100 largest public companies in Mass. by both stock price performance in 2021 and CEO compensation.